24295-06-5

Basic information

• Product Name: 2-(2-Methyl-1,3-dioxolan-2-yl)thiazole
• Synonyms: 2-(2-Methyl-1,3-dioxolan-2-yl)thiazole;2-(2-Methyl-1,3-dioxolan-2-yl)-1,3-thiazole
• CAS NO: 24295-06-5
• Molecular Formula: C₇H₉NO₂S
• Molecular Weight: 171.21686
• Mol File: 24295-06-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(2-Methyl-1,3-dioxolan-2-yl)thiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-Methyl-1,3-dioxolan-2-yl)thiazole(24295-06-5)
• EPA Substance Registry System: 2-(2-Methyl-1,3-dioxolan-2-yl)thiazole(24295-06-5)

Safety Data

• Hazardous Substances Data: 24295-06-5(Hazardous Substances Data)

Usage

General Description

The chemical 2-(2-Methyl-1,3-dioxolan-2-yl)thiazole is a heterocyclic organic compound that contains both a thiazole and dioxolan ring in its structure. It is often used as a flavoring agent in the food industry due to its aromatic properties, and it is also found in some natural products. Additionally, it has been studied for its potential biological activities, including antimicrobial and anti-inflammatory properties. The compound’s unique structure and diverse potential applications make it an interesting target for further research and development in various fields.

Upstream product

• 24295-03-2 2-Acetylthiazole 
• 107-21-1 ethylene glycol 

Downstream Products

• 98025-45-7 2-[1-(hydroxyimino)ethyl]-thiazole 
• 502627-91-0 [2-(2-methyl-1,3-dioxolan-2-yl)-1,3-thiazol-5-yl](phenyl)methanone 
• 774230-98-7 1-(5-bromo-1,3-thiazol-2-yl)ethanone 

Relevant articles and documents

Asymmetric synthesis of (1R,sS,3R)-2-acetyl-5-(1,2,3,4-tetrahydroxybutyl)thiazole

A method for preparing the thiazole analogue 2 of the biologically active compound (1R,2S,3R)-2-acetyl-4(5)-(1,2,3,4-tetrahydroxybutyl)imidazole 1 is reported.

SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.